Peter C Taylor, PhD: Nipocalimab Shows Promise in Rheumatoid Arthritis Treatment


Peter C Taylor, PhD, discusses the efficacy and safety of nipocalimab in patients with active rheumatoid arthritis.

Peter C Taylor, PhD, Norman Collisson professor of Musculoskeletal Sciences at the University of Oxford, sat down with HCPLive to discuss the efficacy and safety of nipocalimab in patients with moderate to severe active rheumatoid arthritis (RA), as evaluated in the IRIS-RA study.

The multicenter, randomized, double-blinded, placebo-controlled phase 2a trial explored the inhibition of the neonatal fragment crystallizable (Fc) receptor (FcRn) in RA. FcRn facilitates the transfer of a specific immunoglobulin class (IgG) across the placenta and plays a crucial role in recycling IgG within the body. However, in autoimmune diseases like RA, where pathogenic autoantibodies exist, hindering this recycling process might be beneficial.

Nipocalimab, the biologic drug studied, targets FcRn, aiming to enhance the breakdown of IgG, particularly pathogenic IgG

The study enrolled approximately 20 patients receiving a placebo and 30 to 32 patients on active treatment. The primary goal was to assess the change in Disease Activity Score-28 for Rheumatoid Arthritis with CRP (DAS28-CRP) at week 12 between groups. Although the primary endpoint did not reach statistical significance and nipocalimab did not affect acute phase markers like CRP, it showed promise in reducing swollen and tender joint counts.

A significant observation was made concerning patients with higher baseline levels of a specific autoantibody, Antibodies to Citrullinated Protein Antigens (ACPA) CCP2. These patients responded particularly well to nipocalimab, indicating these autoantibodies might directly contribute to the disease's symptoms and signs.

However, the overall efficacy of nipocalimab varied among patients, leading to mixed results and the primary endpoint not being met. Still, the study presents opportunities to generate hypotheses for further investigation. For instance, Taylor hypothesized if patients with higher circulating levels of the drug or those with enriched seropositivity could show better responses. Additionally, exploring combination therapy with nipocalimab and agents targeting different immune pathways could yield new insights into treatment.

Related Videos
4 KOLs are featured in this series
4 KOLs are featured in this series
M. Safwan Badr, MD: Novel Treatments for Central Sleep Apnea in Last 10 Years
Video 4 - Featuring 3 KOLs in, "Implementing Treat to Target in the Long-term in Inflammatory Bowel Disease "
Video 3 - Featuring 3 KOLs in, "How important is transmural healing as a treatment target in UC and CD?   Where does intestinal ultrasound fit in CD management?  "
How Elite Athletes Can Optimize Sleep for Peak Performance, with Jesse D. Cook, PhD
Boadie Dunlop, MD, Weighs in on FDA Advisory Vote on Lykos’ MDMA
HCPLive Five at ADA 2024 | Image Credit: HCPLive
© 2024 MJH Life Sciences

All rights reserved.